Jakafi (ruxolitinib)

Jakafi (ruxolitinib) is a prescription medication that targets specific enzymes called JAK1 and JAK2 involved in the body's immune response and blood cell production. It is primarily used to treat myelofibrosis and polycythemia vera, conditions involving abnormal blood cell growth. By inhibiting these enzymes, Jakafi helps reduce symptoms such as spleen enlargement, fatigue, and discomfort, and may slow disease progression. The medication is administered orally and requires careful management by a healthcare professional, as it can affect immune function and blood counts.